Skip to main content
SpringerLink
Log in

STIKO-Empfehlung bisher nur für Mädchen

HPV-Impfung auch für Jungen?

  • Fortbildung
  • Published:
Pädiatrie Aims and scope

In Deutschland empfiehlt die Ständige Impfkommission (STIKO) die HPV-Impfung bisher nur für Mädchen ab neun Jahren. Doch auch Jungen und Erwachsene können von der Immunisierung profitieren. Welche Erfahrungen gibt es diesbezüglich in anderen Ländern? Was hat sich im letzten Jahr beim Impfschema geändert?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Landesuntersuchungsanstalt für das Gesundheits- und Veterinärwesen, Freistaat Sachsen. Infektionsepidemologischer Jahresbericht 2011, verfügbar unter http://www.gesunde.sachsen.de/download/lua/LUA_HM_JB_2011.pdf. 2011

  2. Robert Koch Institut. Infektionsepidemiologisches Jahrbuch. Verfügbar unter http://www.rki.de/DE/Content/Infekt/Jahrbuch/Jahrbuch_2013.pdf?__blob=publicationFile 2013

  3. Scherpenisse M, Mollers M, Schepp RM, et al. Changes in antibody seroprevalence of seven high-risk HPV types between nationwide surveillance studies from 1995-96 and 2006-07 in The Netherlands. PLoS One 2012;7:e48807

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H and de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70–9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Bosch FX, Broker TR, Forman D, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013;31 Suppl 7:H1–31

    Article  PubMed  Google Scholar 

  6. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3–8

    Article  CAS  PubMed  Google Scholar 

  7. Delere Y, Remschmidt C, Leuschner J, et al. Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC Infect Dis 2014;14:87

    Article  PubMed  PubMed Central  Google Scholar 

  8. European Medicines Agency. Gardasil: European public assessment report (EPAR) - Pro-duct Information. Stand: 09.03.2016. Verfügbar unter http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000703/WC500021142.pdf

  9. European Medicines Agency. Cervarix: European public assessment report (EPAR) - Product Information. Stand 02.12.2015. Verfügbar unter http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000721/WC500024632.pdf

  10. European Medicines Agency. Gardasil 9: European Public Assessment Report (EPAR) - Product information. Stand 07.03.2016. Verfügbar unter http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003852/WC500189111.pdf

  11. Ständige Impfkommission am Robert Koch-Institut (RKI). Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August 2014. Epid Bull 2014;34:305–340

    Google Scholar 

  12. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014;89:465-91

  13. Gilca V, Sauvageau C, Boulianne N, et al. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule. Hum Vaccin Immunother 2014;10:2438–45

    Article  PubMed  Google Scholar 

  14. Roggendorf H. Erste Erfahrungen zur Akzeptanz der HPV-Impfung. Monatsschrift Kinderheilkunde 2009;10:982–985

    Article  Google Scholar 

  15. Hughes A, Mesher D, White J and Soldan K. Coverage of the English national human pa-pillomavirus (HPV) immunisation programme among 12 to 17 year-old females by area-level deprivation score, England, 2008 to 2011. Euro Surveill 2014;19:pii=20677

    Article  PubMed  Google Scholar 

  16. Poethko-Müller C, Buttmann-Schweiger N and KiGGS Study Group. [HPV vaccination coverage in German girls: results of the KiGGS study: first follow-up (KiGGS Wave 1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2014;57:869–77

    Article  PubMed  Google Scholar 

  17. de Casadevante VF, Cuesta JG, Valentiner-Branth P and Cantarero-Arévalo L. Uptake in the temporary HPV vaccination programme for females born in 1985-1992. Verfügbar unter http://www.ssi.dk/English/News/EPI-NEWS/2014/No%2047%20-%202014.aspx. EPI-NEWS 2014;47

    Google Scholar 

  18. Bundeszentrale für gesundheitliche Aufklärung. Jugendsexualität - Repräsentative Wiederholungsbefragung von 14-17-jährigen und ihren Eltern. Verfügbar unter http://www.bzga.de/pdf.php?id=f0ba37381b0354c60910ae16171f182d. 2006

  19. Chow EP, Read TR, Wigan R, et al. Ongoing decline in genital warts among young hete-rosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2014

    Google Scholar 

  20. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009;339:b3884

    Article  PubMed  PubMed Central  Google Scholar 

  21. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928–43

    Article  CAS  PubMed  Google Scholar 

  22. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915–27

    Article  Google Scholar 

  23. Joura EA, Giuliano AR, Iversen OE, et al. A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. N Engl J Med 2015;372:711–23

    Article  CAS  PubMed  Google Scholar 

  24. Munoz N, Manalastas R, Jr., Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009;373:1949–57

    Article  CAS  PubMed  Google Scholar 

  25. Olsson SE, Kjaer SK, Sigurdsson K, et al. Evauation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009;5:696–704

    Article  CAS  PubMed  Google Scholar 

  26. Hillman RJ, Giuliano AR, Palefsky JM, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol 2012;19:261–7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Moreira ED, Jr., Palefsky JM, Giuliano AR, et al. Safety and reactogenicity of a quadrivaent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Hum Vaccin 2011;7:768–75

    Article  PubMed  PubMed Central  Google Scholar 

  28. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364:401–11

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010;28:6858–67

    Article  PubMed  Google Scholar 

  30. Van Damme P, Olsson SE, Block S, et al. Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics 2015;136:e28–e39

    Article  PubMed  Google Scholar 

  31. Korostil IA, Ali H, Guy RJ, Donovan B, Law MG and Regan DG. Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males. Sex Transm Dis 2013;40:833–5

    Article  PubMed  Google Scholar 

  32. Jin F, Prestage GP, Kippax SC, et al. Risk factors for genital and anal warts in a prospec-tive cohort of HIV-negative homosexual men: the HIM study. Sex Transm Dis 2007;34:488–93

    PubMed  Google Scholar 

  33. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365:1576–85

    Article  CAS  PubMed  Google Scholar 

  34. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010;10:845–52

    Article  PubMed  PubMed Central  Google Scholar 

  35. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human pa-pillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002;35:1127–34

    Article  PubMed  Google Scholar 

  36. Simard EP, Pfeiffer RM and Engels EA. Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med 2010;170:1337–45

    Article  PubMed  PubMed Central  Google Scholar 

  37. Levin MJ, Moscicki AB, Song LY, et al. Safety and immunogenicity of a quadrivalent hu-man papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010;55:197–204

    Article  PubMed  PubMed Central  Google Scholar 

  38. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010;202:1246–53

    Article  PubMed  PubMed Central  Google Scholar 

  39. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males—Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1705-8

  40. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recom-mendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014;63:1–30

    PubMed  Google Scholar 

  41. National Advisory Committee on Immunization NACI. Update on Human Papillomavirus HPV Vaccines. Verfügbarunter http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/1238/acs-dcc-1/assets/pdf/12-38-acs-dcc-1-eng.pdf. Canada Communicable Disease Report 2012; 381 – 62

  42. Kirby T. Australia to be first country to vaccinate boys against HPV. Lancet Oncol 2012;13:e333

    Article  PubMed  Google Scholar 

  43. Lenzi A, Mirone V, Gentile V, et al. Rome Consensus Conference - statement; human papilloma virus diseases in males. BMC Public Health 2013;13:117

    Article  PubMed  PubMed Central  Google Scholar 

  44. Bundesministerium für Gesundheit. Impfplan Æsterreich. Verfügbar unter http://bmg.gv.at/home/Schwerpunkte/Praevention/Impfen/Oesterreichischer_Impfplan_2014. 2014

  45. Sächsische Impfkommission. Empfehlungen der Sächsischen Impfkommission zur Durchführung von Schutzimpfungen im Freistaat Sachsen (Impfempfehlung E1) Stand: 01.01.2014. Verfügbar unter https://www.slaek.de/de/03/36impfen/pdf/E1_2014.pdf 2014

Download references

Author information

Authors and Affiliations

  1. Institut für Allgemeinmedizin, Ludwig-Maximilians-Universität München, Pettenkoferstr. 8a, 80336, München, Deutschland

    Jörg Schelling

  2. Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität München, München, Deutschland

    Andreas Dietrich

  3. Sektion Klinische Infektiologie Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität München, München, Deutschland

    Ulrich Seybold

Authors
  1. Jörg Schelling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Dietrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ulrich Seybold
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Interessenkonflikt

Die Autoren erklären, dass bei der Erstellung des Beitrags kein Interessenkonflikt vorlag.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schelling, J., Dietrich, A. & Seybold, U. HPV-Impfung auch für Jungen?. Pädiatrie 28, 20–24 (2016). https://doi.org/10.1007/s15014-016-0657-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15014-016-0657-3

Search

Navigation